Anti-FcyR IgM monoclonal antibodies (mAbs) isolated from lipopolysaccharide-stimulated spleen cells from tightskin (TSK) mice were found to be polyspecific, reacting with a wide variety of molecules, including double-stranded DNA, topoisomerase, RNA polymerase, and different collagen types. Approximately 60% of the polyspecific IgM mAbs have anti-Fr,R specificity. These anti-FoyR mAbs induce the release of hydrolases from both azurophil and specific granules ofhuman neutrophils. 25-45% of the total cellular content (determined in Nonidet P-40 lysates) of neutrophil elastase, 10-25% of fl-glucuronidase, and 30-50% of alkaline phosphatase was released after incubation with the mAbs. The degranulation process was accompanied by dramatic morphological changes shown by scanning and transmission electron microscopy. The release of hydrolytic enzymes stimulated by the IgM . anti-FcyR mAbs was inhibited by preincubation of neutrophils with Fab fragments of either anti-human FcYRII (IV3) or anti-human FcyRIII (3G8) mAbs. The binding of the anti-FcyR TSK mAbs to human neutrophils was inhibited by Fab fragments of mAb 3G8 . However, we found that the TSK anti-Fc,R mAbs do not bind to human Fc,RII expressed in either CHO cells or the P388D1 mouse macrophage cell line. Since the enzyme release could be inhibited by Fab fragments of mAb IV3, we suggest that the signal transduction may require FcyRII activation subsequent to crosslinking of the glycan phosphatidyl inositol-anchored FcyRIII-1 . These data demonstrate for the first time that polyspecific autoantibodies with FcyR specificity can trigger neutrophil enzyme release via human FcyRIII-1 in vitro and indicate a possible role for such autoantibodies in autoimmune inflammatory processes.
Organ injury due to inflammatory processes is a fundamental sign ofmany autoimmune diseases. Autoantibodies and immune complexes that are the hallmark of autoimmunity can trigger inflammation by several pathways. Immune complexes can activate the complement system resulting in generation of chemotactic peptides and deposition of C3b and C3bi, which are ligands for complement receptors on neutrophils and macrophages. Immune complexes may also interact directly with FvyP s on effector cells, resulting in release ofhydrolases, activated oxygen intermediates, and cytokines (1, 2) . Other autoantibodies upon interaction with their antigens such as acetylcholine receptor directly trigger pathogenic events (3) .
We have recently reported the presence of high levels of anti-FcyR autoantibodies in different mouse strains prone to autoimmune diseases such as NZB, NZB/NZW Tightskin (TSK)', and viable-motheaten (4) . Moreover, some IgM 'Abbreviations used in this paper: DHFR, dihydrofolate reductase; GPI, glyran phosphatidyl inositol; PSS, progressive systemic sclerosis; TSK, tightskin. mAbs generated from spleen cells of these animals bound to murine FcyRII . The mAbs with FcyR specificity comprise a subset (60%) of polyspecific IgM mAbs. Both serum from autoimmune mice and IgM anti-FcyR mAbs were able to inhibit specifically the binding of immune complexes in vitro to macrophages. These anti-FcyR autoantibodies may be responsible for the paralysis of macrophage FcyR function seen in peritoneal macrophages isolated from autoimmune mice (5) .
Human anti-FcyR receptor antibodies have been demonstrated in SLE andjuvenile neutropenia (6) (7) (8) . Furthermore, in diseases such as Sjogren's syndrome, rheumatoid arthritis, and lupus (9), there is often a paralysis of FcyR function similar to that observed in the murine models for autoimmunity. Functional studies are required to assess the importance of these polyspecific anti-Fr-,R antibodies in the pathology of autoimmune disease . In this report, we present evidence that anti-FcyR autoantibodies have a profound effect on human neutrophils, resulting in release of hydrolytic enzymes contained in both specific and azurophil granules.
Materials and Methods
Monoclonal Antibodies from TSK Mice. Splenic lymphocytes from 2-and 10-mo-old TSK mice, stimulated with LPS (25 Ag/ml) for 2 d, were fused with SP2/0 myeloma cells as described (10, 11) . Supernatants from hybridomas were tested by an ELISA for binding to truncated mouse Fc,,RII0 (12) that was coated onto microtiter wells (4) . The truncated Fc,.RI10 contained only the extracellular domains of the receptor. To prevent nonspecific binding via the Fc domain, the truncated Fc,.R was denatured by reduction and alkylation . 5 of 440 hybridomas had specificity for Fc,.R, and these hybridomas were expanded and cloned by limiting dilution . Antibodies were purified by affinity chromatography on a rat anti-mouse rc-specific mAb Sepharose-4B column . All the anti-Fc,R mAbs were of the IgM class.
Isolation of Human Neutrophils. Peripheral blood drawn from healthy individuals was anticoagulated with heparin and diluted 1:3 with HBSS. The blood (20 ml) was carefully layered on top of a two-step gradient made from 1.119 g/ml Ficoll and 1.077 g/ml Ficoll (10ml each) (Sigma Chemical Co ., St . Louis, MO) (13) . After centrifugation (23 min, 24°C, 1,000 g) in a swinging bucket rotor, the neutrophils were collected, washed, and resuspended in RPMI containing 10% FCS.
Expression of Human Fc.,RII in P388DI and CHO Cells. We obtained a human (hu) Fc,.RIIa cDNA (14, 15) that was cloned into the EcoRI restriction site of the pGEM-4 vector from Dr. Kochan (Hoffman LaRoche, Nutley, NJ). The cDNA was then subcloned into the EcoRl site of pcEXV3 (16), a eukaryotic expression vector with an SV40 early gene promoter. Plasmid DNA from both positive (expressing) orientation and negative orientation huFc,.Rlla-containing bacterial transformants was purified on a CsCl gradient (17) for use in calcium phosphate-DNA coprecipitate transfections as described (18) . Dihydrofolate reductase (DHFR)-negative CHO cells (DG44) were cotransfected with huFcRI1a-pcEXV3 and a DHFR minigene-containing plasmid, pMG1 (19) . CHO transfectants were selected using hypoxanthine-deficient media. P388D1 cells were cotransfected with huFcRIla-pcEXV3 and LK444 (20) , a plasmid with a neomycin resistance gene. The only modification of the calcium phosphate coprecipitation method required to transfect the P388D1 cells was the addition of 10014M chloroquine (Sigma Chemical Co.) to the transfection media. P388D1 transfectants were selected by adding 200 mg/liter of Geneticin (Sigma Chemical Co.) to the growth media. The ability of transfectants to bind mAb IV3, an anti-huFcRII antibody, was analyzed on an Epics cytofluorograph (Coulter Electronics Inc., Hialeah, FL) with three decades of amplification (21) .
Binding Studies. mAbs 3G8, TSKI, TSK22, TSK26, and TSK40 were conjugated with FIX (22) . 5 x 105 neutrophils were incubated in 0.25 ml with the antibodies (1 Etg/ml) for 45 min on ice. The cells were then washed and fixed with 3% paraformaldehyde in PBS. Analysis was done on an Epics cytofluorograph with three decades of amplification. Mean fluorescence peak channels were converted to relative fluorescence to facilitate comparison of inhibition and binding studies. To quantify the amount of FITCIg bound per cell, the fluorescence of appropriate dilutions of the FITC-conjugated Ig and stained cells was determined in a fluorescence spectrometer (650-10S; The Perkin-Elmer Corp., Norwalk, CT) with excitation and emission monochromators set at 480 and 520 nm, respectively.
Stimulation of Neutrophils by Anti-fc.,.R Autoantibodies. Neutrophils suspended in RPMI supplemented with 10% FCS were plated in 24-well tissue culture plates (Costar Electronics Inc.) at 10 6 cells/well . The original medium was removed after 30 min and 1474 replaced with 1 ml of Ig (0 .01-10 mg/ml) diluted in RPMI containing 10% FCS. Aliquots of cell supernatants were taken at intervals to follow the course of enzyme release. In blocking experiments to study the effect of the anti-Fc,,RIII mAb 3G8 and the anti-Fc,RII mAb IV3, the mAbs (or their Fab fragments) were added to the cells for 1 h before they were replaced with the antiFc,R autoantibodies. mAb IV3 and its Fab fragment were purchased from Medarex (Hanover, NH). mAb 3G8 and 3G8-Fab were prepared in our laboratory as described (23) .
Enzyme Assays. All enzyme determinations were carried out on 96-well microtiter plates in triplicate . To quantify enzyme release, dilutions of neutrophil-conditioned supernatants or lysates were mixed with appropriate substrates and buffers and read in a microplate reader (MR600; Dynatech Laboratories Inc., Alexandria, VA). /3-glucuronidase was assayed by cleavage of phenolphthalein-/3-glucosiduronic acid (Sigma Chemical Co .) as described (24) . Supernatant (501Al) was added to the substrate (30 Al of 3 .3 mM phenolphthalein-/3-glucosiduronic acid in 0.067 M acetate buffer, pH 4.5). After incubation (3 h, room temperature) the reaction was developed by addition of glycine buffer (20 pl, 0.4 M, pH 10 .5) and read at 540 nm . Neutrophil elastase activity was assayed by the cleavage of N-t-BOC-ala-pro-nva thiobenzyl ester (Sigma Chemical Co.) in the presence of 5,5'-dithio-bis-(2-nitrobenzoic acid) (Ellman's reagent) (Pierce Chemical Co ., Rockford, IL), which reacts with the free sulfhydryl of the liberated thiobenzyl group (25) . Supernatant (25 Al) was added to the reaction mixture (75 ul, 4.5 mM peptide, 0.33 mM Ellman's reagent, in PBS, pH 7.4, containing 10% DMSO), incubated at room temperature for 1 h, and read at 410 nm . Alkaline phosphatase activity was measured by cleavage of p-nitrophenyl phosphate (26) . Supernatant (50 Al) was added to the reaction mixture (50 Al, 6 mM p-nitrophenyl phosphate, 1 mM ZnCI2, 1 MM MgC12, 0.1 M glycine buffer, pH 10 .0), incubated at 37°C for 1 h, and read at 410 nm . To determine total cellular enzyme content, neutrophils were lysed with 1 ml of 0.5% NP 40 for 10 min, and cleared of nuclei and particulate matter by centrifugation (20 min at 14,000 g) . The cleared lysate supernatant was used in assays for determinations of total cellular enzyme .
Scanning Electron Microscopy. Neutrophils (106 cells/well) were plated on round coverslips (12 mm diameter, no. 1) (Propper SGA Scientific Inc., Bloomfield, NY) in 24-well tissue culture plates in RPMI containing 10% FCS. After 30 min, complete medium containing the different anti-Fc,.R antibodies was added. At intervals, the antibody-containing medium was removed and the cells were fixed for 30 min (1 .5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4) and postfixed (1% osmium in 0.1 M cacodylate buffer) (27) for 1 h. The coverslips were dehydrated, critical point dried, and viewed in a scanning electron microscope (S-530 ; Hitachi) at 6,000x . Some duplicate coverslips were kept in 1% cacodylate buffer after osmium treatment. These coverslips were examined using a 50 x objective with Nomarsky (differential interference optics) on an Axiomat microscope (Carl Zeiss, Inc., Thornwood, NJ) .
Transmission Electron Microscopy. For transmission electron microscopy, neutrophils were incubated with the anti-Fc,,R mAbs or controls in suspension . After fixation (2% glutaraldehyde in 0.1 M cacodylate buffer, 1 MM C2C12) for 30 min, the cells were collected by centrifugation and postfixed (1% reduced osmium in 0.1 M cacodylate buffer) (27) for 1 h on ice. The samples were dehydrated, embedded, and silver-gold sections cut on a microtome (MT5000; Sorvall) . The grids were stained with uranyl acetate and lead citrate (28, 29) and photographed at x 8,000 on an electron microscope (H-7000; Hitachi) .
Results
TSK mice are considered to be a good animal model of human progressive systemic sclerosis (PSS) . These mice develop a scleroderma-like syndrome, accompanied with cutaneous hyperplasia and increased transcription of collagen genes (30, 31) . The old TSK mice also produce autoantibodies for topoisomerase I (11), which are characteristic for human progressive systemic sclerosis and are not found in patients with morphea or CREST syndrome (32) . Because the highest levels of circulating anti-Fcy R autoantibodies were found in sera of TSK mice (4), we isolated monoclonal anti-Fc y R autoantibodies from TSK mice and investigated the possible functional effect of those antibodies.
Characterization of Anti-FcyR IgM Antibodies from TSK Mice. 440 LPS-stimulated hybridomas generated from old TSK mice were screened with different antigens known to be targets of scleroderma autoantibodies . All the screening for anti-FcyR mAbs was done on microtiter plates coated with reduced and alkylated truncated FcyRII0 (12) . The mAbs obtained therefore do not depend upon native conformation of the FcyR for binding, as do the two anti-Fc yR mAbs 3G8 (anti-human FcyRIII) and 2AG2 (anti-rnurine Fc y RII) . The mAbs that were identified in the ELISA for anti-FcyR mAbs were examined further for binding to topoisomerase I, RNA polymerase, collagen I and III, and dsDNA. The TSK antibodies weidentified in the initial screen were all polyspecific, and constitute a subset (60%) of all polyspecific antibodies found, which we defined as mAbs reacting with three disparate antigens. Within the subset of antiFcyR polyspecific mAbs, there were differences in the fine specificity. TSKI, TSK22, and TSK23, for example, were not reactive with dsDNA (results not shown) . We were concerned, in particular, with the possible rheumatoid factor activity of the mAbs, which would complicate analysis of the effect the mAbs had on neutrophil function . The anti-FcyR mAbs did not exhibit binding to murine IgG1. All the mAbs specific for mouse FcyR bind strongly to human neutrophils (Fig. 1) . Cells stained with FITC-3G8 are -12 .5-fold brighter than the isotype control. There are differences among the staining properties of the five antiFcy R mAbs . TSK1 and TSK40 stain somewhat more intensely than TSK22, TSK23, and TSK26 . Since the mAbs were coupled directly with FITC, we could quantify the amount of antibody bound by fluorescence spectroscopy. We found that 72,000 TSK1 IgM molecules bound per neutrophil, compared with 480,000 3G8 IgG molecules per cell (Table  1) . Since the IgM is decavalent, the number of IgM TSK1 molecules that bind is probably a 5-10-fold underestimate of the number of FcyR sites reactive with the antibody.
Human neutrophils express both FcyRII (CD32) and Fcy RIII-1, (CD16), which is a glycan phosphatidyl inositol (GPI)-anchored protein . Human neutrophils are reported to express from 150,000 (23, 33, 34) to 400,000 (35) Fcy RIII-1 molecules per cell . The number of Fcy RII sites on neutrophils is much lower, 15,000-35,000 sites/cell (33, 34) . We conclude from the number of IgM TSKI molecules bound that the mAb must react with FcyRIII. This result is con- firmed by the inhibition of TSK1 binding to neutrophils preincubated with increasing concentrations of 3G8 Fab (Table 1) . To determine if the various TSK antibodies also bound to human Fc,RII, we used transfectants expressing Fc y RII . We first tested a CHO line transfected with FcyRIIa (CW14) and untransfected CHO cells. The CW14 line expressed high levels of FcyRII, determined by binding o£ mAb IV.3 ( Fig.  2 ) compared with the untransfected control, which was the same as the isotype control . We determined by Scatchard analysis that the CW14 line expresses 2 .5 x 105 FcyRII molecules/cell (data not shown) . There was no difference in staining by the TSK mAbs between the control and FcyRII-expressing CHO cells. The distribution of CW14 cells that stain with mAb IV3 (specific for FcyRII) is very broad, indicating considerable heterogeneity in levels of expression. However, the distributions offluorescence intensity of CHO cells stained with the TSK mAbs are all relatively narrow. Thus, To support this conclusion, we examined a mouse macrophage cell line, P388D1, transfected with Fc,RII . This cell line, PW16, expresses 1 .2 x 106 FcyRII molecules/cell as determined by Scatchard analysis (data not shown), and also expresses murine Fc yRII at -2.5 x 105 sites/cell . PW16 and the control P388D1 cells transfected with the insert in the opposite orientation, CPW00, show comparable fluorescence staining by TSK22 (Fig. 3) . The staining of both the transfected and control P388D1 lines is inhibited substantially and to the same extent by mAb 2 .4G2, which reacts specifically with mouse Fc y RII . There is, however, no inhibition of TSK22 binding after addition of mAb IV3 . These results are consistent with the results found for the Fc y RIItransfected CHO cells (Fig. 2) , and show that the TSK mAbs do not react with human Fc,RII .
Enzyme Release. All the IgM antibodies specific for FcyR triggered neutrophil degranulation . We used /3-gluc- uronidase and neutrophil elastase as markers for azurophil granule release and alkaline phosphatase as a marker for specific granule release. The IgM anti-FcyR mAbs trigger degranulation very efficiently. Enzyme release over background levels was found at mAb concentrations as low as 0.01 Ag/ml, (10-ü M) for alkaline phosphatase (Fig. 4 C) . Normal mouse IgM, even at 10 Wg/ml, did not trigger enzyme release over background at any time interval. The extent of degranulation was estimated by measuring the extent of enzyme release and normalizing by the total cellular enzyme present in NP-40 1ysates of neutrophils . The release of neutrophil elastase was 25-45% of total (Fig. 4 A) , /3-glucuronidase was 10-25% of total (Fig. 4 B) , and alkaline phosphatase was 30-50% of total (Fig. 4 C) . The values are comparable with the release found after stimulation with FMLP, which at high concentrations is a potent stimulus of degranulation (36) . We found that mAbs 3G8 and IV3 did not trigger degranulation (data not shown) . These results are in agreement with others (37, 38) , who found that there was no activation triggered by anti-Fc yRII or FcyRIII mAbs unless the mAbs were crosslinked with anti-mouse IgG F(ab')2 . To determine the Fc y R class on the neutrophil plasma membrane involved in triggering by the TSK anti-Fc yR mAbs, we examined the effect of preincubating the cells with Fab fragments of mAbs 3G8 and IV 3 . The cells were preincubated with both Fab fragments separately and in combination, and then the IgM anti-FcyR antibodies were added . There is dramatic inhibition in each enzyme assay with all three combi- 1477 Boros et al . nations of Fab fragments, even with IV.3 Fab alone (Fig. 5) , thus demonstrating that in a functional assay, both Fcy RII and FcyRIII are required .
Morphology.
Given the extensive enzyme release triggered by the autoantibodies, we would expect to observe accompanying morphological changes . We examined neutrophils incubated with mAb TSK23 for 3 min and control cells incubated with normal mouse IgM by scanning electron microscopy. Averaged over 20 cells, the diameter of control neutrophils was greater (8 .2 ± 1 .3 Am) than that of neutrophils incubated with TSK23 (6 .2 ± 0.6 Am) (p < 0.01). These results were confirmed by differential interference contrast microscopy (results not shown) . The surface morphology of the cells is dramatically different in the presence of anti-Fc Y R antibody (Fig. 6) . The cells treated with anti-FcyR antibody (Fig. 6, C and D) lack the large pseudopods and lamellae seen in control neutrophils (Fig. 6, A and B) .
Transmission electron microscopy was carried to understand better the morphological changes occurring after stimulation with anti-Fc yR antibodies from TSK mice. Relative to the control neutrophils (Fig. 7 A) , the surface of the neutrophils incubated with TSK23 (Fig . 7 B) shows fewer membrane ruffles and infoldings, in agreement with the scanning results . The stimulated neutrophils have fewer large storage vesicles, and a much higher number of small vesicles than the control neutrophils . These results are consistent with extensive degranulation, and subsequent internalization of excessive membrane into smaller vesicles, resulting in a smaller cell volume . 
Discussion
Several inbred mouse strains used as models for autoimmune diseases, including NZB, NZB/NZW, TSK, and viable motheaten mice, have high circulating levels of IgM anti-mouse F_,RII autoantibody. In old NZB females, -16 Ag/ml, or 2%, of the total IgM bound to an FcyR affinity column (4) . We have shown previously that sera from such mice, as well as IgM anti-Fc yRII mAbs, inhibit macrophage FcyR-mediated binding of immune complexes. These autoantibodies are probably responsible for the FcyR paralysis seen in peritoneal macrophages from autoimmune mice (5) . It was thought that high levels of circulating immune complexes in autoimmune mice caused FcyR paralysis. In support of our hypothesis, peritoneal macrophages from BXSB male mice, which have no detectable anti-FcyR Ig but do have a severe lupus-like syndrome, are normal for macrophage FcyR function . Anti-RyR autoantibodies have been detected in human disease as well, indicating juvenile neutropenia and SLE (6) (7) (8) . We have preliminary evidence that such anti-
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FcyR antibodies are also present in human scleroderma patients (unpublished data) .
We have found that the polyspecific anti-FcyR mAbs isolated from TSK mice bind with high avidity to human neutrophils, and that these autoantibodies efficiently trigger the release of azurophil and specific granule hydrolases . In contrast, mAbs directed against human FcyRIII or FcyRII do not induce hydrolase release without additional crosslinking (38, 39) . The difference in efficacy of the anti-FcyR IgM compared with IgG mAbs may reflect the decavalent nature of IgM, which more efficiently clusters or crosslinks the receptors.
The anti-Fc yR mAbs we isolated from the TSK mice, and the anti-Fr.,R mAbs previously characterized from NZB and me mice, were all polyspecific (4), binding to a wide range of cellular antigens including collagen type I and III, and dsDNA . The polyspecificity of the anti-FcyR mAbs may enhance the potential for possible pathogenicity. If the decavalent IgM autoantibody binds to collagen, for example, it could also bridge to the FcyR of neutrophils or macrophages, activating the release of chemotactic factors as well as hydrolytic enzymes in the immediate vicinity. Such an antibody might also play a role in activation of the mesangial cells of the kidney, which bear FcyRs and can be triggered to release superoxide (40, 41) . The role of polyspecific antibodies in autoimmune diseases is not well understood . Some suggest they are only marginally related to autoimmunity, constituting a natural network (42, 43) . However it should be noted that anti-FcyR autoantibody is not found at detectable levels in normal mice (4) .
In determining which FcyR subclass is responsible for degranulation by the IgM anti-FcyR mAbs, we found evidence that the signaling by the GPI-anchored FcyRIII-1 requires human FcyRII. The anti-FcyR IgM antibodies offer an advantage in analysis of the signalling requirements since they 147 9
Boros et al . do not interact with FcyRs via their Fc domains and they mediate triggering without the need for additional crosslinking . The dramatic enzyme release triggered by IgM antiFc y R mAbs is inhibited by mAb 3G8 Fab (directed against Fcy RIII), and by mAb IV.3 Fab (directed against FcyRII) . The inhibition by mAb 3G8 is probably due to displacement of the IgM anti-FcyR autoantibody, and/or reduction of the extent of crosslinking below the threshold needed to trigger the neutrophil . The inhibition of neutrophil degranulation by the mAb IV3 Fab is a particularly surprising result, given the lack of binding of the anti-Fc y R mAbs from TSK mice to human Fc yRII. The results suggest that signal transduction may require FcyRII activation subsequent to crosslinking of the GPI-anchored FcyRIII-1 molecule. This differs from Kimberly et al. (38) , who suggest that Fcy RIII alone, crosslinked with anti-FcyRIII Fab and anti-mouse IgG F(ab')2, can trigger (Caz+]i flux. The same group finds that Con A-opsonized E also are phagocytosed via Fcy RIII, which bears high mannose oligosaccharides (44) . Signal transduction via neutrophil Fc y RIII-1 may resemble that of other GPI-anchored molecules, such as Thy-1 (45, 46) , the Ly-6-encoded molecule T cell activating protein (TAP) (47, 48) , and 5'-nucleotidase (CD73) (49, 50) . Crosslinking of Thy-1 and TAP results in T cell mitogenesis only in the presence of a functional CD3/Ti complex . Furthermore, the GPI anchor is required for signalling through TAP. Signalling via GPI-anchored proteins also differs fundamentally from the Ti/CD3 complex in that antiTAP mAbs do not trigger T cell mitogenesis when adsorbed to surfaces, but only in solution (51) .
Therefore, there is precedent for the hypothesis that antiFc yR IgM mAb clustering of neutropbil Fcy RIII-1 triggers signalling by activating FcyRIL For crosslinking of FcyRIII-1 to trigger Fc,RII, one must postulate interaction of ectodomains of the receptors, and/or interaction involving the GPI 1480 anchor. The latter is suggested by experiments demonstrating that the GPI anchor is required for TAP triggering (48) . However, the inhibition by the anti-human FcyRII mAb Fab fragment of enzyme release triggered by the IgM anti-FoYR mAb suggests that interaction of the ectodomains is required as well . The phospholipid anchor of erythrocyte acetylcholinesterase has been determined to consist of an 18 :0 or 18 :1 1-alkyl group and unusual unsaturated 22 :4 or 22 :5 2-acyl groups (52) . A microdomain in the plasma membrane consisting exclusively of such phospholipid anchors might have unique properties that would interact with other signalling proteins .
Our results clearly show that the IgM anti-Fc~R mAbs, which are a subset of the polyspecific mAbs found in TSK mice, mediate a dramatic degranulation of human neutrophils . The release of hydrolytic enzymes occurs at extremely low concentrations of IgM mAb, and may be important in inflammation accompanying autoimmunity.
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